TN2015000099A1 - Methods for treatment of alport syndrome - Google Patents

Methods for treatment of alport syndrome

Info

Publication number
TN2015000099A1
TN2015000099A1 TNP2015000099A TN2015000099A TN2015000099A1 TN 2015000099 A1 TN2015000099 A1 TN 2015000099A1 TN P2015000099 A TNP2015000099 A TN P2015000099A TN 2015000099 A TN2015000099 A TN 2015000099A TN 2015000099 A1 TN2015000099 A1 TN 2015000099A1
Authority
TN
Tunisia
Prior art keywords
alport syndrome
mir
treatment
methods
certain embodiments
Prior art date
Application number
TNP2015000099A
Other languages
English (en)
Inventor
Jeremy Duffield
Balkrishen Bhat
Deidre Mackenna
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of TN2015000099A1 publication Critical patent/TN2015000099A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
TNP2015000099A 2012-10-09 2015-03-16 Methods for treatment of alport syndrome TN2015000099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261711514P 2012-10-09 2012-10-09
US201361779137P 2013-03-13 2013-03-13
PCT/US2013/063884 WO2014058881A1 (fr) 2012-10-09 2013-10-08 Méthodes de traitement du syndrome d'alport

Publications (1)

Publication Number Publication Date
TN2015000099A1 true TN2015000099A1 (en) 2016-06-29

Family

ID=49382663

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000099A TN2015000099A1 (en) 2012-10-09 2015-03-16 Methods for treatment of alport syndrome

Country Status (35)

Country Link
US (7) US9012423B2 (fr)
EP (2) EP3620522B1 (fr)
JP (4) JP6272880B2 (fr)
KR (4) KR102165189B1 (fr)
CN (1) CN104718295B (fr)
AR (1) AR092940A1 (fr)
AU (3) AU2013329427B2 (fr)
BR (1) BR112015007709B1 (fr)
CA (1) CA2885605A1 (fr)
CL (1) CL2015000873A1 (fr)
CR (1) CR20150236A (fr)
CY (1) CY1122479T1 (fr)
DK (1) DK2906698T3 (fr)
EA (1) EA201590711A1 (fr)
ES (2) ES2753174T3 (fr)
HK (1) HK1212378A1 (fr)
HR (1) HRP20191948T1 (fr)
HU (1) HUE045858T2 (fr)
IL (2) IL237768B (fr)
LT (1) LT2906698T (fr)
MX (1) MX356340B (fr)
MY (1) MY183921A (fr)
NZ (1) NZ630596A (fr)
PH (1) PH12015500781A1 (fr)
PL (1) PL2906698T3 (fr)
PT (1) PT2906698T (fr)
RS (1) RS60014B1 (fr)
SG (1) SG11201502748RA (fr)
SI (1) SI2906698T1 (fr)
TN (1) TN2015000099A1 (fr)
TW (1) TWI641388B (fr)
UA (1) UA116639C2 (fr)
UY (1) UY35069A (fr)
WO (1) WO2014058881A1 (fr)
ZA (1) ZA201502087B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2302055B1 (fr) 2004-11-12 2014-08-27 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
HUE031595T2 (en) 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
KR20230037703A (ko) 2012-04-25 2023-03-16 사노피 마이크로rna 화합물 및 mir-21 활성 조절 방법
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
WO2015061536A1 (fr) 2013-10-25 2015-04-30 Regulus Therapeutics Inc. Composés de microarn et procédés de modulation de l'activité de mir-21
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CA2955481A1 (fr) * 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Remplacement de collagene iv
WO2016029027A2 (fr) * 2014-08-21 2016-02-25 Stealth Biotherapeutics Corp Méthodes et compositions destinées à prévenir et à traiter une maladie
KR102620328B1 (ko) 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (fr) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Oligomères antisens destinés au traitement du retard mental dominant autosomique 5 et du syndrome de dravet
BR112019009256A2 (pt) 2016-11-08 2019-07-16 Reata Pharmaceuticals Inc métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
WO2018123925A1 (fr) 2016-12-28 2018-07-05 第一三共株式会社 Médicament thérapeutique pour le syndrome d'alport
MA50749A (fr) * 2017-05-04 2020-03-11 Sanofi Sa Méthodes de traitement du syndrome d'alport
EP3878961A1 (fr) 2017-06-06 2021-09-15 Zymergen, Inc. Plate-forme d'ingénierie génomique htp permettant d'améliorer escherichia coli
KR20200026878A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
SG10202108375XA (en) 2017-08-25 2021-09-29 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
GB2584204B (en) * 2017-10-23 2023-06-28 Stoke Therapeutics Inc Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
SG11202104409YA (en) 2018-10-31 2021-05-28 Zymergen Inc Multiplexed deterministic assembly of dna libraries
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
JP2022524043A (ja) 2019-03-08 2022-04-27 ザイマージェン インコーポレイテッド 微生物の反復ゲノム編集
US20230287410A1 (en) 2020-05-11 2023-09-14 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
WO2023217764A1 (fr) * 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Inhibiteurs de nox destinés à être utilisés dans le traitement du syndrome d'alport

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL345946A1 (en) * 1998-05-22 2002-01-14 Boys Town Nat Res Hospital Use of α1β1 integrin receptor inhibitors and tgf-β1 inhibitors in the treatment of kidney disease
KR100574597B1 (ko) * 1998-05-22 2006-04-28 보이스 타운 내셔널 리서치 호스피탈 α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
US20060008817A1 (en) 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP2386637B1 (fr) 2001-09-28 2018-05-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de micro arn
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20050124591A1 (en) * 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
CA2533701A1 (fr) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US7585550B2 (en) 2004-02-02 2009-09-08 College Of William And Mary Process for modifying polymeric surfaces using deep UV irradiation
EP2471924A1 (fr) 2004-05-28 2012-07-04 Asuragen, INC. Procédés et compositions impliquant du microARN
WO2006020768A2 (fr) 2004-08-10 2006-02-23 Alnylam Pharmaceuticals, Inc. Oligonucleotides chimiquement modifies
JP2008512463A (ja) * 2004-09-08 2008-04-24 ボーイズ タウン ナショナル リサーチ ホスピタル マトリックスメタロプロテイナーゼ−１２に関連する糸球体基底膜疾患の治療
EP2302055B1 (fr) 2004-11-12 2014-08-27 Asuragen, Inc. Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi
US20070099196A1 (en) 2004-12-29 2007-05-03 Sakari Kauppinen Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US6995235B1 (en) 2005-05-02 2006-02-07 Univation Technologies, Llc Methods of producing polyolefins and films therefrom
US20090203893A1 (en) * 2005-08-29 2009-08-13 Regulus Therapeutics, Llc Antisense compounds having enhanced anti-microrna activity
EP2388328A1 (fr) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Composés oligomères et compositions pour une utilisation dans la modulation de micro ARN
EP3431602A1 (fr) 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Composition pharmaceutique comprenant des oligonucléotides antisens anti-arnmi
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
MX2009003548A (es) 2006-10-03 2009-04-15 Alnylam Pharmaceuticals Inc Formulaciones que contienen lipidos.
EP2476762B1 (fr) 2006-10-09 2014-01-08 Julius-Maximilians-Universität Würzburg Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques
EP2104735A2 (fr) 2006-12-08 2009-09-30 Asuragen, INC. Gènes et voies génétiques régulés par mir-21 utilisés en tant que cibles pour une intervention thérapeutique
EP2118118B1 (fr) 2007-01-19 2017-09-27 Exiqon A/S Apport cellulaire médié d'oligonucléotides de lna
WO2008151631A2 (fr) 2007-06-15 2008-12-18 Exiqon A/S Utilisation de courts oligonucléotides pour des expériences à redondance de réactif dans une analyse fonctionnelle d'arn
US20080317725A1 (en) * 2007-06-20 2008-12-25 Baum Seth J Compositions and methods of treating chronic kidney disease
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
CA2704043C (fr) 2007-10-29 2018-09-18 Rosetta Genomics Ltd. Ciblage de microarn pour le traitement du cancer du foie
WO2009091972A2 (fr) 2008-01-18 2009-07-23 Alnylam Pharmaceuticals, Inc. Oligonucléotides modifiés chimiquement et petites molécules à utiliser dans la réduction des taux d'activité de microarn et leurs utilisations
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2096171A1 (fr) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg Cibles microARN (miARN) et en aval à des fins de diagnostic et thérapeutiques
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
CA2753562A1 (fr) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Microarn chez les non-fumeurs et methodes et matieres apparentees
SG176716A1 (en) 2009-06-08 2012-01-30 Miragen Therapeutics CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS
WO2011126842A2 (fr) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Ciblage de micro-arn pour le traitement de troubles cardiaques
HUE031595T2 (en) 2011-04-25 2017-07-28 Regulus Therapeutics Inc Micro RNA Compounds s Methods for Modulating Mir-21 Activity
WO2013013165A2 (fr) 2011-07-21 2013-01-24 The Trustees Of The University Of Pennsylvania Utilisation de composés d'acide nucléique bloqué (lna) pour l'inhibition thérapeutique de mir-21 dans le lupus érythémateux systémique
KR20230037703A (ko) 2012-04-25 2023-03-16 사노피 마이크로rna 화합물 및 mir-21 활성 조절 방법
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN104955950B (zh) 2012-09-26 2019-04-26 米尔克斯治疗学公司 具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта

Also Published As

Publication number Publication date
EP2906698A1 (fr) 2015-08-19
HUE045858T2 (hu) 2020-01-28
JP2022110140A (ja) 2022-07-28
TWI641388B (zh) 2018-11-21
US20170369879A1 (en) 2017-12-28
JP2015536301A (ja) 2015-12-21
IL237768B (en) 2018-10-31
CY1122479T1 (el) 2021-01-27
PH12015500781B1 (en) 2015-06-15
AR092940A1 (es) 2015-05-06
AU2019210494A1 (en) 2019-08-15
KR102165189B1 (ko) 2020-10-14
SG11201502748RA (en) 2015-05-28
WO2014058881A1 (fr) 2014-04-17
US20200283765A1 (en) 2020-09-10
AU2013329427B2 (en) 2019-05-02
MX356340B (es) 2018-05-23
US9688986B2 (en) 2017-06-27
HK1212378A1 (en) 2016-06-10
NZ630596A (en) 2017-05-26
ZA201502087B (en) 2016-06-29
EP2906698B1 (fr) 2019-07-31
JP2020073479A (ja) 2020-05-14
US20180298385A1 (en) 2018-10-18
HRP20191948T1 (hr) 2020-04-03
KR20230136686A (ko) 2023-09-26
US20140100263A1 (en) 2014-04-10
US20150299704A1 (en) 2015-10-22
CR20150236A (es) 2015-06-30
PL2906698T3 (pl) 2020-05-18
CN104718295B (zh) 2020-03-13
BR112015007709A2 (pt) 2017-08-08
CN104718295A (zh) 2015-06-17
EP3620522A1 (fr) 2020-03-11
IL262200A (en) 2018-11-29
JP6272880B2 (ja) 2018-01-31
US9970011B2 (en) 2018-05-15
MY183921A (en) 2021-03-17
PT2906698T (pt) 2019-11-05
BR112015007709B1 (pt) 2022-05-17
SI2906698T1 (sl) 2019-11-29
US20160319283A1 (en) 2016-11-03
TW201420120A (zh) 2014-06-01
UY35069A (es) 2014-04-30
KR20220005634A (ko) 2022-01-13
DK2906698T3 (da) 2019-11-04
JP2018080190A (ja) 2018-05-24
EA201590711A1 (ru) 2015-07-30
ES2753174T3 (es) 2020-04-07
KR20200118245A (ko) 2020-10-14
US20220098582A1 (en) 2022-03-31
MX2015004460A (es) 2015-11-23
US9012423B2 (en) 2015-04-21
AU2021269404A1 (en) 2021-12-16
LT2906698T (lt) 2019-11-11
RS60014B1 (sr) 2020-04-30
EP3620522B1 (fr) 2023-07-26
PH12015500781A1 (en) 2015-06-15
KR20150064072A (ko) 2015-06-10
ES2960488T3 (es) 2024-03-05
CA2885605A1 (fr) 2014-04-17
KR102349184B1 (ko) 2022-01-07
US9359609B2 (en) 2016-06-07
UA116639C2 (uk) 2018-04-25
CL2015000873A1 (es) 2015-08-14
AU2013329427A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
PH12015500781B1 (en) Methods for treatment of alport syndrome
HK1211723A1 (en) Methods and formulations promoting tissue organ regeneration, longevity and healthspan
ZA201501541B (en) Supported catalyst and active form thereof, and preparation method and use thereof
CL2013003341A1 (es) Un metodo y sistema para autenticar una sesion de un usuario.
RS20140202A1 (en) BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
BRPI1010718A2 (pt) sistemas modelo e regimes de tratamento para tratar doença neurológica.
MX356210B (es) Formulaciones de polimero acrilico.
WO2009129387A3 (fr) Lipides cationiques et utilisations associees
CA145239S (en) Teapot
MX347620B (es) Derivados de sulfonilaminopirrolidinona, su preparacion y aplicacion terapeutica.
MX2019013158A (es) Metodos para el tratamiento del sindrome de alport.
Havranek et al. Low-cost telemedicine.
AR128192A2 (es) Métodos para el tratamiento del síndrome de alport
AR119688A2 (es) Métodos para el tratamiento del síndrome de alport
EP2814498A4 (fr) Compositions d'oligonucléotide riche en guanosine (gro), procédés et utilisations pour traiter une infection par le virus respiratoire syncytial
WO2014025749A3 (fr) Inhibiteurs à petites molécules des interactions des protéines virales avec l'arnt humain
陸軼峰 Study on the application of ecosystem engineering to wastewater treatment in the decentralized area
CA142814S (en) Medical patch
陈征宇 Understanding DNA chains in confinement by using the wormlike-chain model
卢希 Creek Maze
Fu Winner Takes All: A Belligerent Male Society——Discourse Strategies in Glengarry Glen Ross
周游 What can you do?
PAVAN The Italian Market of Business Angels: Determinants of Performance
童国梁 DESY/CERN
Шапошникова The organization of social work within the framework of socialization of modern youth